- A recognised leader in Market Access and HEOR, Nick Sullivan brings more than two decades of technical, operational, and business building expertise
- With this appointment, Kintiga is strengthening its leadership to deliver a greater impact in addressing the evolving and complex European market access environment
Cambridge, UK, 2 February 2026 – Kintiga, a pan-European specialist market access consultancy, today announced the appointment of Nick Sullivan as Chief Executive Officer. This appointment elevates global leadership as Kintiga begins a new chapter of growth and expansion. Nick is a seasoned leader with more than 25 years of experience in pharmaceutical services and a proven track record in creating exceptional teams and businesses. Most recently, Nick was a Global President and founding executive at Lumanity, where he played a key role in the foundational acquisitions before moving into operational leadership. Nick has also held senior positions at notable specialist firms including Evidera/PPD, United BioSource Corporation, and the Total Healthcare Group. His career commitment to optimising patient access to new medical advances aligns with the long-term strategy and ambition of Kintiga.
Nick said, ‘It’s a privilege to take on the Kintiga CEO role at a critical moment in the firm’s evolution. The access environment is turbulent, and the problems our clients face more complex than ever. We believe that real impact comes from focus – our ambition is to deliver the presence and capabilities our clients need across their most strategically important markets. We will specialise in the areas that can create most value for our clients and provide career-defining experiences for our teams.’
About Kintiga
Kintiga is a pan-European specialist pharmaceutical and biotechnology market access consultancy. Its unique capabilities enable companies to maximise the value of their product portfolios, while providing patients with life-changing health solutions, by facilitating access to medicines across Europe’s complex medical, regulatory and payer environment. Kintiga provides a unique combination of specialist consultancy products and services across the development path to commercialisation, along with an online membership platform providing uninterrupted access to experts, as well as an extensive and unique database, a set of tools, and invaluable content.
Kintiga has operations across the UK, Ireland, Benelux, and Germany, with extensive experience across more than 350 clients and over 540 HTA (Health Technology Assessment) submissions across Europe, including EU Joint Clinical Assessments (JCA).
For more information about Kintiga, visit www.kintiga.com
Media Inquiries:
Marianne Lambertson, Chief Commercial Officer
mlambertson@kintiga.com
